The UK's Innovation Dilemma: Is Britain Pricing Itself Out of the Medicine Market?
The UK spends significantly less of its health budget on branded medicines than comparable nations. Termination rates in the appraisal process have doubled. And companies are increasingly choosing not to launch here at all. A conversation with the ABPI's Jack Neill-Hall about what's at stake—and where the opportunity lies.
